SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
Rosen Law Firm issued a shareholder-solicitation notice for a securities fraud class action against ARS Pharmaceuticals (NASDAQ: SPRY), reminding purchasers of the October 5, 2026 lead plaintiff deadline. The lawsuit alleges defendants misled investors on the timeline for expanded CVS Caremark insurance coverage for the neffy epinephrine nasal spray during a March 9 to June 24, 2026 class period.
Key figures
- Class period
- March 9, 2026 to June 24, 2026
- Lead plaintiff deadline
- October 5, 2026
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.